Your browser doesn't support javascript.
loading
Leveraging multi-source to resolve inconsistency across pharmacogenomic datasets in drug sensitivity prediction.
Das, Trisha; Bhattarai, Kritib; Rajaganapathy, Sivaraman; Wang, Liewei; Cerhan, James R; Zong, Nansu.
Afiliação
  • Das T; University of Illinois Urbana-Champaign, Champaign, Illinois, United States.
  • Bhattarai K; Luther College, Decorah, Iowa, United States.
  • Rajaganapathy S; Department of Artificial Intelligence and Informatics Research, Mayo Clinic, Rochester, MN, USA.
  • Wang L; Department of Molecular Pharmacology and Experimental Therapeutics, Mayo Clinic, Rochester, MN.
  • Cerhan JR; Department of Quantitative Health Sciences, Mayo Clinic, Rochester, MN, USA.
  • Zong N; Department of Artificial Intelligence and Informatics Research, Mayo Clinic, Rochester, MN, USA.
medRxiv ; 2023 Jun 05.
Article em En | MEDLINE | ID: mdl-37333219
ABSTRACT
Pharmacogenomics datasets have been generated for various purposes, such as investigating different biomarkers. However, when studying the same cell line with the same drugs, differences in drug responses exist between studies. These variations arise from factors such as inter-tumoral heterogeneity, experimental standardization, and the complexity of cell subtypes. Consequently, drug response prediction suffers from limited generalizability. To address these challenges, we propose a computational model based on Federated Learning (FL) for drug response prediction. By leveraging three pharmacogenomics datasets (CCLE, GDSC2, and gCSI), we evaluate the performance of our model across diverse cell line-based databases. Our results demonstrate superior predictive performance compared to baseline methods and traditional FL approaches through various experimental tests. This study underscores the potential of employing FL to leverage multiple data sources, enabling the development of generalized models that account for inconsistencies among pharmacogenomics datasets. By addressing the limitations of low generalizability, our approach contributes to advancing drug response prediction in precision oncology.

Texto completo: 1 Bases de dados: MEDLINE Tipo de estudo: Diagnostic_studies / Prognostic_studies / Risk_factors_studies Idioma: En Revista: MedRxiv Ano de publicação: 2023 Tipo de documento: Article País de afiliação: Estados Unidos

Texto completo: 1 Bases de dados: MEDLINE Tipo de estudo: Diagnostic_studies / Prognostic_studies / Risk_factors_studies Idioma: En Revista: MedRxiv Ano de publicação: 2023 Tipo de documento: Article País de afiliação: Estados Unidos